Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 20, 2017 | June 22, 2017 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Commercial | September 02, 2026 | September 03, 2026 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | July 02, 2018 | July 03, 2018 |
| Sio Gene Therapies Inc.AXON · Entity 130622 | Principal Operating Officer | April 07, 2017 | April 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.78 · Expires 2027-06-19 | Direct | 14,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 14,000 · Balance 14,000 F1: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date.
REGENERON PHARMACEUTICALS, INC.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,003 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Sale · Disposed 1,215 · Balance 13,134 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. Row 2 · 2026-09-03 · Sale · Disposed 1,131 · Balance 12,003 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 219 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 219 |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
SCYNEXIS INC
Report date July 02, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2028-07-01 | Direct | 9,217 |
Reported balance
After 2018-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-02 · Grant · Acquired 9,217 · Balance 9,217 F1: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy.
Sio Gene Therapies Inc.
Report date April 07, 2017 · Filed April 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.13 · Expires 2027-04-07 | Direct | 465,000 |
Reported balance
After 2017-04-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-07 · Grant · Acquired 465,000 · Balance 465,000 F1: 25% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2016-09-28 · Other · Disposed 541 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 40,453 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.58 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 80,905 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Represents shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016.
F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,131 | $857.39 | $969,708.09 |
DisclosureSEC source: 0001663758-26-000002 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,003 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,215 | $850.00 | $1,032,750.00 |
DisclosureSEC source: 0001663758-26-000002 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,134 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,021 | $701.51 | $716,241.71 |
DisclosureSEC source: 0001663758-25-000009 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,349 Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,336 | $712.94 | $952,487.84 |
DisclosureSEC source: 0001663758-25-000007 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,370 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,210 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0001663758-25-000007 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,210 Underlying: Common Stock · 12,210 shares Expires 2035-12-05 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001663758-25-000007 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,706 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 759 | $730.81 | $554,684.79 |
DisclosureSEC source: 0001883850-24-000063 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,230 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 274 | $787.00 | $215,638.00 |
DisclosureSEC source: 0001968202-24-000136 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,989 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,981 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001968202-24-000136 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,981 Underlying: Common Stock · 8,981 shares Expires 2034-12-06 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000136 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,263 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001968202-24-000132 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 1,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $844.61 | $844,610.00 |
DisclosureSEC source: 0001968202-24-000132 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $381.40 | $381,400.00 |
DisclosureSEC source: 0001968202-24-000132 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001968202-24-000129 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 1,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $1,054.06 | $1,054,060.00 |
DisclosureSEC source: 0001968202-24-000129 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $381.40 | $381,400.00 |
DisclosureSEC source: 0001968202-24-000129 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001968202-24-000125 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 1,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $1,178.73 | $1,178,730.00 |
DisclosureSEC source: 0001968202-24-000125 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $381.40 | $381,400.00 |
DisclosureSEC source: 0001968202-24-000125 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,137 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001883850-24-000040 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,137 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,137 | $1,060.86 | $1,206,197.82 |
DisclosureSEC source: 0001883850-24-000040 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,137 | $372.46 | $423,487.02 |
DisclosureSEC source: 0001883850-24-000040 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,137 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001968202-24-000106 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,137 Underlying: Common Stock · 1,137 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,137 | $1,047.11 | $1,190,564.07 |
DisclosureSEC source: 0001968202-24-000106 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,137 | $372.46 | $423,487.02 |
DisclosureSEC source: 0001968202-24-000106 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,138 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001968202-24-000100 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,274 Underlying: Common Stock · 1,138 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,138 | $980.16 | $1,115,422.08 |
DisclosureSEC source: 0001968202-24-000100 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,138 | $372.46 | $423,859.48 |
DisclosureSEC source: 0001968202-24-000100 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $889.41 | $222,352.50 |
DisclosureSEC source: 0001883850-24-000018 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $964.73 | $241,182.50 |
DisclosureSEC source: 0001968202-24-000089 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,181 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 358 | $967.50 | $346,365.00 |
DisclosureSEC source: 0001968202-24-000083 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,431 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $934.71 | $934,710.00 |
DisclosureSEC source: 0001968202-24-000052 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,789 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 273 | $945.61 | $258,151.53 |
DisclosureSEC source: 0001968202-24-000046 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,789 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 274 | $873.91 | $239,451.34 |
DisclosureSEC source: 0001883850-24-000004 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,062 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 5,105 | $856.71 | $4,373,504.55 |
DisclosureSEC source: 0001968202-23-000056 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,336 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 373 | $844.09 | $314,845.57 |
DisclosureSEC source: 0001883850-23-000088 · edgardoc.xml · nonDerivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,441 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 270 | $838.44 | $226,378.80 |
DisclosureSEC source: 0001883850-23-000088 · edgardoc.xml · nonDerivative · entry 3 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,649 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001883850-23-000088 · edgardoc.xml · derivative · entry 6 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,649 Underlying: Common Stock · 7,649 shares Expires 2033-12-08 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000088 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,084 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 852 | $843.79 | $718,909.08 |
DisclosureSEC source: 0001883850-23-000088 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,951 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001883850-23-000079 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $783.91 | $783,910.00 |
DisclosureSEC source: 0001883850-23-000079 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,803 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $381.40 | $381,400.00 |
DisclosureSEC source: 0001883850-23-000079 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,038 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001968202-23-000035 · edgardoc.xml · derivative · entry 4 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,412 Underlying: Common Stock · 1,038 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,038 | $827.00 | $858,426.00 |
DisclosureSEC source: 0001968202-23-000035 · edgardoc.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,803 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,038 | $372.46 | $386,613.48 |
DisclosureSEC source: 0001968202-23-000035 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $834.55 | $208,637.50 |
DisclosureSEC source: 0001968202-23-000033 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,803 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $744.66 | $186,165.00 |
DisclosureSEC source: 0001968202-23-000019 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,053 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $710.09 | $177,522.50 |
DisclosureSEC source: 0001968202-23-000017 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,303 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $736.00 | $184,000.00 |
DisclosureSEC source: 0001883850-23-000072 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · EVP Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,553 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.